uPAR CAR T Cells Eradicate Solid Tumors by Targeting Tumor Ecosystem
Recent preclinical research published in the journal Cell demonstrates a novel approach to treating solid tumors using uPAR-positive Chimeric Antigen Receptor (CAR) T cell therapy. The study highlights that these engineered T cells effectively target both tumor cells and the surrounding stromal tissue, creating a convergent attack on the tumor ecosystem. When synergized with senescence-inducing therapies, this method successfully eradicates both primary and metastatic solid tumors in preclinical models. A significant advantage of this approach is the minimal myelodepletion observed, addressing a common safety concern in intensive cancer treatments. By focusing on the uPAR marker, which is present in both malignant cells and the supportive stroma, the therapy overcomes the heterogeneity often found in solid tumors. This dual-targeting strategy suggests a broad vulnerability in solid tumor ecosystems that can be exploited for more effective cancer treatment. The findings represent a promising advancement in immunotherapy, potentially offering a viable solution for cancers that have historically been resistant to traditional CAR T cell therapies due to their complex microenvironment.
Wire timeline
uPAR CAR T Cells Eradicate Solid Tumors by Targeting Tumor Ecosystem
Recent preclinical research published in the journal Cell demonstrates a novel approach to treating solid tumors using uPAR-positive Chimeric Antigen Receptor (CAR) T cell therapy. The study highlights that these engineered T cells effectively target both tumor cells and the surrounding stromal tissue, creating a convergent attack on the tumor ecosystem. When synergized with senescence-inducing therapies, this method successfully eradicates both primary and metastatic solid tumors in preclinical models. A significant advantage of this approach is the minimal myelodepletion observed, addressing a common safety concern in intensive cancer treatments. By focusing on the uPAR marker, which is present in both malignant cells and the supportive stroma, the therapy overcomes the heterogeneity often found in solid tumors. This dual-targeting strategy suggests a broad vulnerability in solid tumor ecosystems that can be exploited for more effective cancer treatment. The findings represent a promising advancement in immunotherapy, potentially offering a viable solution for cancers that have historically been resistant to traditional CAR T cell therapies due to their complex microenvironment.
Cell